Welcome to our dedicated page for Aptose Biosciences news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences stock.
Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS) is a clinical-stage biotechnology company dedicated to developing precision medicines for the treatment of life-threatening cancers. This science-driven organization is focused on advancing first-in-class agents targeting acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. Based on a deep understanding of the genetic and epigenetic profiles of specific cancers and patient demographics, Aptose is building a robust pipeline of novel oncology therapies aimed at dysregulated processes and signaling pathways.
One of Aptose's pioneering agents, tuspetinib (TUS), is a highly potent, first-in-class pan-FLT3/BTK inhibitor. Developed as a small molecule therapeutic, tuspetinib targets various key kinases such as SYK, FLT3, JAK1/2, and mutant forms of KIT, RSK2, and TAK1-TAB1. This mechanism of action not only combats the proliferation of AML cells but also minimizes the typical cytotoxic side effects associated with conventional cancer treatments, thus enhancing the quality of life for patients.
Tuspetinib has shown significant promise in ongoing clinical trials. In the APTIVATE Phase 1/2 study, tuspetinib, both as a monotherapy and in combination with venetoclax (VEN), has demonstrated favorable safety profiles and robust efficacy in relapsed/refractory AML patients. This includes patients with various genetic mutations and those who have failed prior therapies. Notably, tuspetinib has demonstrated a 48% overall response rate when used in combination with venetoclax, making it a potential candidate for accelerated approval in difficult-to-treat VEN-resistant AML cases.
Aptose is also developing luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor currently in Phase 1 a/b development. Luxeptinib targets relapsed or refractory hematologic malignancies and is being positioned for future clinical trials using its new generation 3 (G3) formulation, which has shown improved pharmacokinetics and tolerability.
Recently, Aptose has entered strategic financial transactions, including a public offering and private placement, to support the further development of tuspetinib and general corporate activities. With strong clinical data and robust financial backing, Aptose continues to make strides in the oncology field, aiming to bring life-saving treatments to patients in need.
Aptose Biosciences announced the results of its annual meeting held on June 1, 2021, where 72.83% of shareholders participated. All board nominees were elected, with Carol G. Ashe receiving 99.25% of votes for her position. Key resolutions passed included the reappointment of KPMG LLP as auditors, approval of the 2021 Stock Incentive Plan, and the 2021 Employee Stock Purchase Plan. Additionally, shareholders supported a non-binding resolution for executive compensation. Details on these results are available on SEDAR and EDGAR.
Aptose Biosciences (NASDAQ: APTO) announced a corporate update scheduled for June 11, 2021, at 8:00 AM ET during the EHA2021 Virtual Congress. The update will highlight clinical data for two investigational products: luxeptinib (CG-806), a FLT3 and BTK kinase inhibitor in trials for relapsed or refractory acute myeloid leukemia (AML) and B-cell malignancies, and APTO-253, a MYC repressor for patients with relapsed AML or high-risk myelodysplastic syndromes (MDS). Early clinical data will also be presented in posters on June 11, 2021.
Aptose Biosciences, a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Virtual Conference is set for May 19, 2021, from 11:30 AM to 11:55 AM EDT, featuring a fireside chat with Gregory J. Renza, M.D. The Jefferies Virtual Healthcare Conference follows on June 2, 2021, at 2:00 PM EDT, where Aptose will present a slide deck and host a webcast. The company focuses on developing innovative cancer therapeutics, including luxeptinib and APTO-253, aimed at treating various hematological malignancies.
Aptose Biosciences (NASDAQ: APTO) reported a net loss of $16.2 million for Q1 2021, up from $11.5 million in Q1 2020. Research and development expenses rose to $8.2 million, driven by increased costs for luxeptinib and APTO-253 trials. The company continues dose escalations in its Phase 1 a/b studies for luxeptinib in AML and B-cell malignancies. Dr. Jotin Marango has been appointed as Chief Financial Officer. Aptose maintains a solid cash position of $112.1 million, expected to support operations into 2023. Updates on clinical trials are anticipated at the upcoming EHA Virtual Congress in June.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) will announce its financial results for Q1 2021 on May 4, 2021, after market close. The announcement will be followed by a conference call at 4:30 PM ET. Investors can access the call via dial-in or webcast. The Q1 report will include financial statements and management’s discussion available on SEDAR and EDGAR. Aptose focuses on developing therapies for unmet needs in oncology, particularly in hematology, with investigational products luxeptinib and APTO-253 undergoing clinical trials.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference on April 15, 2021, from 3:00 to 3:55 PM EDT. CEO William G. Rice, Ph.D. will join a panel discussing opportunities in BPDCN and AML, moderated by John Newman, Ph.D.
The company focuses on developing personalized therapies for oncology, particularly hematology. Their pipeline includes luxeptinib, a mutation-agnostic FLT3/BTK inhibitor, and APTO-253, which targets the MYC oncogene.
Aptose Biosciences Inc. (NASDAQ: APTO) reported a net loss of $14.7 million for Q4 2020, increasing to $55.2 million for the full year, attributed mainly to higher R&D and stock-based compensation expenses. The company continues to progress in its clinical trials for luxeptinib and APTO-253, with encouraging early signs of anti-cancer activity. Additionally, CFO Gregory Chow is resigning, with Dr. William Rice taking over as Chief Accounting Officer. As of December 31, 2020, Aptose had $122.4 million in cash, sufficient to support operations through mid-2023.
Aptose Biosciences announces key management appointments to enhance clinical development and regulatory functions. George Melko, Pharm.D., joins as Vice President of Regulatory Affairs, bringing over 20 years of oncology regulatory experience from companies like Tmunity and Incyte. Robert Killion, Ph.D., appointed Vice President of CMC, has over 20 years in manufacturing and quality control from firms such as Gilead and Roche. These hires aim to support ongoing Phase 1 trials of CG-806 and APTO-253, reinforcing Aptose's commitment to advancing innovative cancer therapies.
Aptose Biosciences Inc. (Nasdaq: APTO) will release its financial results for the year and quarter ended December 31, 2020, on March 23, 2021, after market close. The company is focused on developing therapeutics targeting cancer mechanisms, particularly in hematology. Aptose's clinical pipeline includes CG-806, a first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, and APTO-253, which directly targets the MYC oncogene. Both products are currently in clinical trials.
Aptose Biosciences has initiated dosing of the first patient in a Phase 1 a/b clinical study for CG-806, an oral kinase inhibitor targeting acute myeloid leukemia (AML). The starting dose of 450mg was selected based on previous safety and efficacy data in chronic lymphocytic leukemia (CLL) trials. This multicenter, open-label study aims to evaluate the drug's safety and pharmacodynamics in relapsed or refractory AML patients. The company is also conducting another Phase 1 study for B-cell malignancies.
FAQ
What is the current stock price of Aptose Biosciences (APTO)?
What is the market cap of Aptose Biosciences (APTO)?
What does Aptose Biosciences specialize in?
What is tuspetinib?
What are the recent achievements of Aptose Biosciences?
What is luxeptinib?
How does Aptose aim to improve the quality of life for cancer patients?
What financial activities has Aptose recently undertaken?
What are the main clinical trials conducted by Aptose?
What makes tuspetinib a potential candidate for accelerated approval?
How does Aptose integrate genetic insights into its drug development?
What is the strategy behind Aptose's targeted therapies?
